Nuvalent
preliminary efficacy radiographic tumor regression observed across all dose levels | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
21 of 39
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
preliminary activity phase induced tumor response across heavily patient populations radiographic tumor regression observed across all dose levels data as of for response evaluable patients with treated by central nervous system not evaluable objective response rate progressive disease partial response once daily response evaluation criteria in solid version stable disease tyrosine kinase inhibitor footnotes for waterfall two patients and dose cohorts both with prior therapies consisting of and chemotherapy not shown due to incomplete or missing post tumor assessments in the setting of and symptomatic deterioration single not confirmed ongoing partial responses pending confirmation best response due to residual disease additional prior was including and investigational therapy source a patients with a best response all response evaluable resistance mutation history of metastases prior and prior or chemotherapy a includes ongoing partial responses pending confirmation includes ongoing partial response pending confirmation patient discontinued treatment due to clinical progression without post radiographic assessment these prior were discontinued due to progressive disease in patients key be dose level cohort prior prior lines chemotherapy prior lines anticancer therapy liss us us | Nuvalent
Investor Presentation
April 2024
preliminary activity radiographic tumor response in patients with and without known alk resistance mutations phase no mutation single or compound mutation a key i dose level cohort prior a prior lines chemotherapy prior lines anticancer therapy data cut off august response evaluable four response evaluable no single or compound not shown due to incomplete or missing post assessments the setting of or symptomatic deterioration mutation as per any prior local testing or central analyses progressive disease partial once daily stable disease tyrosine kinase inhibitor evidence of allelic configuration mutation variant of unknown significance ongoing partial responses pending confirmation single not confirmed additional was including investigational therapy source lin i i | Nuvalent
Investor Presentation
February 2024
preliminary activity phase induced tumor response across heavily patient populations radiographic tumor regression observed across all dose levels data as of for response evaluable patients with treated by central nervous system not evaluable objective response rate progressive disease partial response once daily response evaluation criteria in solid version stable disease tyrosine kinase inhibitor footnotes for waterfall two patients and dose cohorts both with prior therapies consisting of and chemotherapy not shown due to incomplete or missing post tumor assessments in the setting of and symptomatic deterioration single not confirmed ongoing partial responses pending confirmation best response due to residual disease additional prior was including and investigational therapy source a patients with across all dose levels best response all response evaluable resistance mutation history of metastases prior and chemotherapy prior or i includes ongoing partial responses pending confirmation includes ongoing partial response pending confirmation patient discontinued treatment due to clinical progression without post radiographic assessment these prior were discontinued due to progressive disease in patients key i a i a dose level cohort prior prior lines chemotherapy prior lines anticancer therapy a | Nuvalent
Investor Presentation
February 2024
preliminary activity radiographic tumor response in patients with and without known alk resistance mutations phase no mutation single or compound mutation key so as a dose level cohort prior prior lines chemotherapy prior lines anticancer therapy i data cut off august response evaluable four response evaluable no single or compound not shown due to incomplete or missing post assessments the setting of or symptomatic deterioration mutation as per any prior local testing or central analyses progressive disease partial once daily stable disease tyrosine kinase inhibitor evidence of allelic configuration mutation variant of unknown significance ongoing partial responses pending confirmation single not confirmed additional was including investigational therapy source lin i i | Nuvalent
Related slides by other companies
BioNTech
Results
November 2020
safety trial in patients with malignant solid tumors who are not bot | BioNTech
Morgan Stanley
Investment Banking
August 2022
orange comparable regression analysis | Morgan Stanley
Kymera
Results
December 2022
degradation profile of and in consistent with preclinical models in blood and tumor bent | Kymera
Kymera
Investor Presentation
June 2023
overall safety | Kymera
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io